Cost-effectiveness of Using Quantiferon Gold (QFT-G)® versus Tuberculin Skin Test (TST) among U.S. and Foreign Born Populations at a Public Health Department Clinic with a Low Prevalence of Tuberculosis

Public Health Nursing

Volumn 31, Issue 2, 2014, Pages 144-152

  Iqbal, Ayesha Z ^a   Leighton, Jenelle ^a   Anthony, John ^a   Knaup, Richard C ^a   Peters, Eleanor B ^a   Bailey, Thomas C ^b  

^a St Louis County Department of Health   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; LTBI; Screening; TST; Tuberculosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COST BENEFIT ANALYSIS; COST-EFFECTIVENESS; ECONOMICS; FEMALE; HUMAN; LTBI; MALE; METHODOLOGY; MIDDLE AGED; MIGRATION; PREVALENCE; PUBLIC HEALTH; SCREENING; SENSITIVITY AND SPECIFICITY; STATISTICS; TST; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES; YOUNG ADULT;

COST-EFFECTIVENESS; LTBI; SCREENING; TST; TUBERCULOSIS;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; EMIGRATION AND IMMIGRATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES; YOUNG ADULT;

EID: 84895194480     PISSN: 07371209     EISSN: 15251446     Source Type: Journal    
DOI: 10.1111/phn.12083     Document Type: Article

References (23)

1. Bennett, D. E., Courval, J. M., Onorato, I., Agerton, T., Gibson, J. D., Lambert, L., et al. (2008). Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. American Journal of Respiratory and Critical Care Medicine, 177(3), 348-355. doi:10.1164/rccm.200701-057OC.
2. Brock, I., Weldingh, K., Lillebaek, T., Follmann, F., & Andersen, P. (2004). Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. American Journal of Respiratory and Critical Care Medicine, 170(1), 65-69. doi:10.1164/rccm.200402-232OC.
3. Cohn, D. L., O'Brien, R. J., Geiter, L. J., Gordin, F., Hershfield, E., & Horsburgh, C. (2000). Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Morbidity and Mortality Weekly Report, 49(6), 1-54.
4. Dewan, P. K., Grinsdale, J., Liska, S., Wong, E., Fallstad, R., & Kawamura, L. M. (2006). Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infectious Diseases, 6, 47. doi:10.1186/1471-2334-6-47.
5. Diel, R., Nienhaus, A., & Loddenkemper, R. (2007). Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest, 131(5), 1424-1434. doi:10.1378/chest.06-2728.
6. Ferebee, S. H. (1970). Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibliotheca Tuberculosea, 26, 28-106.
7. Franken, W. P., Timmermans, J. F., Prins, C., Slootman, E.-J. H., Dreverman, J., Bruins, H., et al. (2007). Comparison of Mantoux and QuantiFERON TB Gold tests for diagnosis of latent tuberculosis infection in Army personnel. Clinical and Vaccine Immunology, 14(4), 477-480.
8. Geiter, L. e. (2000). Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, D.C: The National Academies Press.
9. Johnson, P., Stuart, R., Grayson, M., Olden, D., Clancy, A., Ravn, P., et al. (1999). Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clinical and Diagnostic Laboratory Immunology, 6(6), 934-937.
10. Khan, K., Wang, J., Hu, W., Bierman, A., Li, Y., & Gardam, M. (2008). Tuberculosis infection in the United States: national trends over three decades. American Journal of Respiratory and Critical Care Medicine, 177(4), 455-460.
11. Machado, A., Szabo, K., Barbosa, T., Arruda, S. M., Reis, M. G., Riley, L. W., et al. (2007). Comparison of whole blood interferon-gamma assay with tuberculin skin testing in household contacts of pulmonary tuberculosis patients in Salvador, Brazil. Chest, 132(4_MeetingAbstracts), 433a-433.
12. Mazurek, G. H., Jereb, J., LoBue, P., Iademarco, M. F., Metchock, B., & Vernon, A. (2005). Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recommendations and Reports, 54, 49-55.
13. Mazurek, G., Jereb, J., Vernon, A., LoBue, P., Goldberg, S., Castro, K., et al. (2010). Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recommendations and Reports, 59, 1-25.
14. Mori, T., & Harada, N. (2005). Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. Kekkaku, 80(11), 675.
15. Nienhaus, A., Schablon, A., Costa, J. T., & Diel, R. (2011). Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Services Research, 11(1), 247.
16. Pai, M., Joshi, R., Dogra, S., Mendiratta, D. K., Narang, P., Kalantri, S., et al. (2006). Serial testing of health care workers for tuberculosis using interferon-γ assay. American Journal of Respiratory and Critical Care Medicine, 174(3), 349-355.
17. Pai, M., Zwerling, A., & Menzies, D. (2008). Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Annals of Internal Medicine, 149(3), 177.
18. de Perio, M. A., Tsevat, J., Roselle, G. A., Kralovic, S. M., & Eckman, M. H. (2009). Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Archives of Internal Medicine, 169(2), 179.
19. Pratt, R., Robison, V., Navín, T., Hlavsa, M., & Pevzner, E. (2007). Centers for Disease Control and Prevention (CDC). Trends in tuberculosis incidence-United States, 2006. Morbidity and Mortality Weekly Report, 56, 245-250.
20. Rajbhandary, S., Marks, S., & Bock, N. (2004). Costs of patients hospitalized for multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 8(8), 1012-1016.
21. Shah, M., Miele, K., Choi, H., DiPietro, D., Martins-Evora, M., Marsiglia, V., et al. (2012). QuantiFERON-TB gold in-tube implementation for latent tuberculosis diagnosis in a public health clinic: a cost-effectiveness analysis. BMC Infectious Diseases, 12(1), 360.
22. Small, P. M., & Fujiwara, P. I. (2001). Management of tuberculosis in the United States. New England Journal of Medicine, 345(3), 189-200.
23. Taylor, Z., Marks, S., Burrows, N. R., Weis, S., Stricof, R., & Miller, B. (2000). Causes and costs of hospitalization of tuberculosis patients in the United States. International Journal of Tuberculosis and Lung Disease, 4(10), 931-939.